Abstract
Study of a randomly selected sample of 202 stable ketoacidosis-resistant diabetics aged 35–80 revealed that, subjects receiving phenformin hydrochloride (DBI) alone or in combination therapy had significantly lower serum cholesterol and triglyceride levels than matched diabetics treated with insulin or tolbutamide alone. A prospective study of 60 additional diabetics previously treated with diet or tolbutamide or untreated showed that phenformin as the sole therapeutic agent produced a 12 per cent fall in cholesterol, a 40 per cent fall in triglycerides, an 11 per cent fall in fasting blood sugar and a weight loss of 3 4 to 1 pound/month (average values). The average dose of phenformin was 85 mg. daily and the average period of treatment was 26 weeks. These findings were interpreted in light of current concepts of the interrelationship of disorders of carbohydrate and lipid metabolism and the mechanism of action of phenformin was considered.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
